Aridis Pharma Says Phase 2a Study Of AR-501 In Cystic Fibrosis Meets Endpoints
Aridis Pharmaceuticals, Inc. (ARDS) announced Monday preliminary top-line results from the randomized, double blinded, placebo-controlled Phase 2a study of AR-501, which evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as an inhaled aerosol in cystic fibrosis (CF) patients with confirmed Pseudomonas aeruginosa bacterial and other potential infections.
Aridis Pharmaceuticals Inc More Such Health News Cystic Fibrosis Foundation Aridis Pharmaceuticals Cystic Fibrosis R 501
Source: rttnews.com